Skip to main content
. 2014 May 29;111(1):46–54. doi: 10.1038/bjc.2014.236

Figure 4.

Figure 4

Changes in Ki-67 expression for patients at baseline and post-treatment histology according to treatment received. The large majority of patients randomised receiving (A) exemestane plus celecoxib (EXE-COXIB arm) and (B) exemestane alone (EXE arm) showed a suppression of Ki-67.